PubMed Latest

CONCLUSIONS: Within this population, ~ 85% of responders maintained SALT scores ≤ 20 through approximately 4 years with continued benefit for EB/EL. Baricitinib's safety profile remained consistent over 5 years of treatment, in line with prior BRAVE program findings.

CONCLUSION: Skin lesions in dental professionals and students, particularly dental technicians, are shown to be linked to acrylate exposure in this first Croatian study. Consequently, the implementation of additional protective measures is highly recommended.

INTRODUCTION: Bardet-Biedl syndrome (BBS) is a multisystem ciliopathy characterized by progressive retinal degeneration alongside metabolic, renal, endocrine, and neurodevelopmental manifestations, resulting in profound quality of life (QoL) impairment. In the absence of disease-modifying therapies, patient- and caregiver-reported outcomes (ROs) are essential for capturing disease burden and informing care and future interventions.

CONCLUSION: Artificial intelligence-assisted quantitative RCM can identify age-associated epidermal morphometric features, predominantly in the SG, and detect their modulation following topical treatment. XEP™-716 Miniprotein™ at 2.5% showed consistent treatment-associated changes across several morphometric parameters with nominal statistical significance. These exploratory findings warrant prospective validation against molecular senescence markers and functional barrier measurements.

CONCLUSIONS: In GBA-PD, STN-DBS treatment at later stages is associated with greater risk of cognitive decline. Earlier STN-DBS intervention in GBA-PD may extend the period of improved motor function before the onset of significant cognitive decline. These findings highlight the potential importance of early genetic testing and disease duration when considering STN-DBS in genetically defined PD populations. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of...